Officials at Adaptimmune, which focuses on cell therapies targeting solid tumors, say the company has built in-house bioprocessing capabilities to avoid shortages in outsourcing capacity for cell and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback